Sept and Nov were explosive SP months for Kazia last year. I expect similar this year with KEY inflection points to share price: * Any positive data from the current trials (4 due) by EOY. * Any partnerships for Paxalisib / Cantrixil * Any start of new trials ~ GBM Agile / Cantrixil * Any news pertaining to DIPG specifically after obtaining PRDD. * Any submission of FDA application / approval Don't forget; FDA application and or approval can come at ANY time. Know what you have / Know why you have it
KZA Price at posting:
84.0¢ Sentiment: Buy Disclosure: Held